All In Biotech

Drug Trial Radar · NCT02456740

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 955 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

955

Actual

Start

Jul 17, 2015

Primary completion

Sep 5, 2016

Study completion Jun 19, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.

Conditions

  • Migraine

Interventions

  • ErenumabDrug

    Administered by subcutaneous injection once a month

  • PlaceboDrug

    Administered by subcutaneous injection once a month

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment PeriodTime frame: 4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase

Locations

129 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Anaheim, California

  • Research Site

    Encino, California

  • Research Site

    Irvine, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Newport Beach, California

  • Research Site

    Rancho Mirage, California

  • Research Site

    Redlands, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Simi Valley, California

  • Research Site

    Spring Valley, California

  • Research Site

    Boulder, Colorado

  • Research Site

    East Hartford, Connecticut

  • Research Site

    Stamford, Connecticut

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Bradenton, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Leesburg, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Sunrise, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Evansville, Indiana

  • Research Site

    Des Moines, Iowa

  • Research Site

    Newton, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Edgewood, Kentucky

  • Research Site

    Metairie, Louisiana

  • Research Site

    New Orleans, Louisiana

  • Research Site

    New Bedford, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Plymouth, Minnesota

  • Research Site

    Kansas City, Missouri

  • Research Site

    Springfield, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Amherst, New York

  • Research Site

    Plainview, New York

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.